Wilbanks Smith & Thomas Asset Management LLC Reduces Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Wilbanks Smith & Thomas Asset Management LLC reduced its position in CRISPR Therapeutics AG (NASDAQ:CRSPGet Rating) by 95.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,830 shares of the company’s stock after selling 66,767 shares during the period. Wilbanks Smith & Thomas Asset Management LLC’s holdings in CRISPR Therapeutics were worth $214,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of CRSP. Nikko Asset Management Americas Inc. lifted its stake in shares of CRISPR Therapeutics by 31.3% in the 4th quarter. Nikko Asset Management Americas Inc. now owns 4,319,471 shares of the company’s stock valued at $330,526,000 after purchasing an additional 1,029,955 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in CRISPR Therapeutics during the fourth quarter worth $21,717,000. Marshall Wace LLP acquired a new position in CRISPR Therapeutics during the third quarter worth $28,624,000. Goldman Sachs Group Inc. raised its position in CRISPR Therapeutics by 327.9% during the third quarter. Goldman Sachs Group Inc. now owns 328,082 shares of the company’s stock worth $36,722,000 after acquiring an additional 251,401 shares during the period. Finally, SG Americas Securities LLC raised its position in CRISPR Therapeutics by 118.1% during the fourth quarter. SG Americas Securities LLC now owns 23,150 shares of the company’s stock worth $1,754,000 after acquiring an additional 151,194 shares during the period. Hedge funds and other institutional investors own 55.21% of the company’s stock.

A number of equities research analysts have recently issued reports on CRSP shares. The Goldman Sachs Group dropped their target price on shares of CRISPR Therapeutics from $179.00 to $87.00 and set a “neutral” rating for the company in a report on Thursday, February 17th. Brookline Capital Acquisition started coverage on shares of CRISPR Therapeutics in a report on Monday, February 14th. They set a “buy” rating and a $143.00 target price for the company. Royal Bank of Canada dropped their target price on shares of CRISPR Therapeutics from $117.00 to $95.00 and set a “sector perform” rating for the company in a report on Wednesday, February 16th. Barclays dropped their target price on shares of CRISPR Therapeutics from $148.00 to $107.00 in a report on Wednesday, February 16th. Finally, Credit Suisse Group initiated coverage on shares of CRISPR Therapeutics in a report on Thursday. They issued a “neutral” rating and a $78.00 price objective for the company. One analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $125.43.

Shares of CRSP traded down $2.00 during mid-day trading on Friday, hitting $49.62. 973,977 shares of the company’s stock were exchanged, compared to its average volume of 1,007,989. The company has a market cap of $3.84 billion, a price-to-earnings ratio of 11.23 and a beta of 2.02. CRISPR Therapeutics AG has a fifty-two week low of $48.38 and a fifty-two week high of $169.76. The stock’s 50-day moving average is $60.78 and its 200-day moving average is $71.40.

CRISPR Therapeutics (NASDAQ:CRSPGet Rating) last issued its quarterly earnings results on Monday, February 14th. The company reported ($1.84) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.74) by ($0.10). The business had revenue of $12.90 million for the quarter, compared to analyst estimates of $5.39 million. CRISPR Therapeutics had a return on equity of 16.21% and a net margin of 41.28%. As a group, research analysts predict that CRISPR Therapeutics AG will post -7.69 EPS for the current fiscal year.

About CRISPR Therapeutics (Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Read More

Institutional Ownership by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.